Statement by Mr. Nicolas Sarkozy, President of the Republic, on efforts in favor of the health industries, in Paris on October 26, 2009.

France Nicolas Sarkozy · President of France

26 October 2009 · Meeting with leaders of health industries (strategic council of health industries) · Élysée Palace, Paris, France

Context
Sarkozy addressed leaders of major health industry groups at the Élysée Palace in Paris to outline France's strategy for supporting the pharmaceutical and biotech sectors amid industry disruption.
Main themes
Health industries reform, pharmaceutical sector challenges, patent expiration and generic drugs, biotechnology and biomedical research, French innovation policy, university autonomy, research tax credit, biomedical research investment, trade balance in pharmaceuticals, public-private partnerships
Duration
~19 min
63rd percentile
Words
2,288
63rd percentile
Sentences
144
79th percentile
Readability
56
78th percentile
Grade
9.4
14th percentile
Syntax
2.70
13th percentile
Vocabulary
2.22
53rd percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 57%56%
  • Social 15%15%
  • Institutional 14%14%
  • Ceremonial 9%9%
  • Geopolitical 3%3%
  • Technological 3%3%
  • Environmental 0%0%
  • Not in focus 1%

144 sentences in 30 paragraphs

Ladies and gentlemen ministers,

Ladies and gentlemen presidents and directors general,

Ladies and gentlemen,

I would first like to welcome you to France, on behalf of all the French people, at least for those who are not French, and to welcome you to the Élysée for the others. The schedule of the meeting has been changed, and I would like to ask you to excuse me for that, and I warmly thank you for making yourselves available.

I am pleased to welcome here the leaders of the largest health industry groups, both French and foreign. The strategic council of health industries has just met in the presence of ministers and in your presence.

Your companies are all prosperous, and we commend that. They all have, to varying degrees, operations and staff in France. However, the health industries, particularly the pharmaceutical sector, are about to face what will likely be the most difficult period in your history over the next five years. Difficult because you will have to deal with the expiration of patents for the best-selling drugs, and the revenues of your companies will, for some of you, decrease by 20, 30, or even 40%! This is a historic drop and thus a disruption that awaits you.

Generic drugs will represent 15% of the global pharmaceutical market in 2012, up from 9% in 2000. They allow for a balance between quality of care and economic performance.

That's not all. The health industries, which have built their development on chemistry, are now increasingly dependent on biological products. The share of biotechnology in the global pharmaceutical market will rise from 10% to over 15% during the period from 2007 to 2012. Biotechnology may not create jobs en masse, as traditional chemistry has done. But biotechnology will create high value-added jobs.

Under the guise of biotechnology, some may be tempted to sell dreams. We must be vigilant, even if biotechnology will be an essential factor for well-being and health for humanity in the coming decades.

The generification of drugs, the rise of biotechnology: these are broad, rapid movements that will completely change the strategic context of the health industries. That is why we are gathered here today. The French public authorities are fully aware of the challenges that lie ahead.

I would like to convince you that France has all the assets to meet these challenges with you. France is transforming, and France wants to remain a great country for innovation and for the health industries.

Our pharmaceutical industry is one of the largest in the world. Let me be clear, we will do everything to ensure it remains so. The trade balance of the sector had a surplus of over 7 billion euros in 2008 and should remain so in 2009.

French medicine and research are among the best in the world. And I will do everything to ensure they remain so. In 2008 and 2009, France ranked first in life and health sciences, ahead of the United Kingdom and Germany, for the number of winners of the European Research Council's "young researchers" call for proposals.

France is the third or fourth largest pharmaceutical market in the world, but it is more than just that. France is a land of excellence for biomedical research, and I ask you to consider it as such. These are not just words; these are decisions we have made.

The world has experienced the era of "blockbuster" drugs sold for several billion euros for very common diseases that are now properly treated - I think of hypertension. Why should we not expect other major breakthroughs? Because there are still so many ailments without cures: cancer, AIDS, Alzheimer’s, rare diseases.

I know well that research is made up of unforeseen events, encounters, and sometimes pleasant surprises. And we must know how to seize the opportunity. I would even say that we must give chance a chance. Valérie Pécresse has led, with my full support, the autonomy of French universities. It was awaited for four decades. It is now a reality. And when there was contestation, we did not back down an inch, because we believe that the future of French universities lies in autonomy. The reform of university hospitals, which Roselyne Bachelot has remarkably conducted - this concerns 1,100,000 people - has been carried out in a calm social climate, without drama. This reform had been awaited for several decades. And then there was the creation of the Alliance for Life and Health Sciences. French public research is, as you know, undergoing a renaissance, and we are dedicating funding to it like it has never received in past decades. Your own research teams are opening up to the outside. Forge partnerships with the best research teams in the world. Our researchers are among the best in certain fields, such as neuroscience, immunology, cardiovascular health, and genetics. Our researchers are ready to work with you.

With Christine Lagarde, whom I thank, we have established a research tax credit - I affirm - that is one of the most favorable in the world. I tell foreign industrialists who invest in France: the research tax credit that we have tripled is one of the most favorable in the world. And I announce to you that its immediate reimbursement, decided as part of the stimulus plan, will be extended to 2010 in the finance bill. This is not a decision we made for one year; it is a decision that, together with the Minister of Finance, we made to make France a land of research. Taxation will be put at the service of research. The Alliance for Life and Health Sciences is intended to be the unique agency for programming biomedical research, modeled after the American National Institutes of Health. It is not about copying; it is about taking the best practices from outside France to apply them to our country. I have long believed that France has exhausted the expertise of what did not work elsewhere, to now explore what does work. About ten regional companies will be set up in 2010 to bring universities and businesses together around the valorization of patents. Our universities will once again become the heart of French research. We are establishing the conditions for a new partnership between the Alliance, our best universities, and you, the industrialists.

I know that in some research organizations, there are still inertias, hesitations, and apprehensions about greater integration of the Alliance. I want to be perfectly clear on this subject and leave no room for doubt. The Alliance must quickly evolve towards integrated operational governance. Otherwise, how do you expect our industrial partners to find their way and trust us? This integrated governance that I expect from the Alliance is the condition for the success of all our industrial partnerships, and thus for the valorization of our research and our growth. We will not wait, we will not yield, because it is in the interest of France.

You committed, during the strategic council, to double the amount of resources dedicated to collaborations with research in our country. I thank you for that. You are also contributing, alongside the Strategic Investment Fund, to the "Biotechnology" fund, which amounts to 140 million euros. This is a testimony of trust that France will prove worthy of.

We can together meet the challenge of industrial employment. France is the leading European producer of medicines. The health industries represent 350,000 direct and indirect jobs. The development of generics and biotechnology poses a threat to these jobs. We had to react.

I say to both French and foreign industrialists, we will do everything to maintain industrial employment. I do not believe in a great country that does not remain a land of production. I believe in industry; I have believed in it since the beginning of my political career. I have not changed my mind. The professional tax is being reformed. And I thank Christine Lagarde and the Prime Minister for their firmness. I was elected to fight against deindustrialization and relocations; do not think that I will yield; it is my priority. We will eliminate the taxation of investments. What a strange idea it was to create a tax that taxes investments since 1975 when France needs them to create jobs and benefit from growth. All governments, whether left or right, have said all the bad things they thought about the professional tax and have carefully kept it. We are abolishing it. Companies will therefore benefit from a tax reduction of 12 billion euros in 2010. I am pleased that our great partner and friend Germany is making the same choice as ours, that of tax reduction. At a time when I hear calls from both the left and the right to increase taxes, I want to reiterate that I was not elected to raise taxes. There will be no tax increase; there will be tax reductions. It is through tax reductions and strengthening the competitiveness of France that we will allow the French to have the jobs they need and the growth we need. Increasing taxes has been done for so long by left and right governments to the great detriment of growth. So let it be clear, the course is set, and it will not change. I am pleased that our main partner, Germany, has made the same choice. I will have the opportunity to meet with Madam Merkel the day after tomorrow, and we will discuss it in detail. And that will mean 6 billion euros less in taxes in steady state. I can announce to you that the reform of the professional tax was adopted by the National Assembly last Friday. This represents, for the pharmaceutical industry, a 16% reduction in the professional tax contribution. 16% in the current context.

We will develop bioproduction sites. Sanofi-Aventis will create a site in Vitry-sur-Seine, near Paris, that will manufacture batches of biological products. Other locations will follow. Our country has several hundred biotechnology SMEs. We have significant innovation potential. It would be a shame if this potential did not translate into the creation of new industrial jobs.

France will also take its share in the production of generics. We will not allow industrial jobs that contribute to the production of so-called "originator" drugs to leave simply because they are now generic. Generics are a fundamental trend in your industry. We must adapt to it.

We will encourage industrialists who agree to have generics of their drugs produced in France a few weeks before the expiration of the patent. This measure should allow our country to face, on equal terms with other states, the phenomenon of generification. Otherwise, we can be sure that generics will be produced elsewhere than in France. Several thousand jobs are at stake. I want to strengthen the competitiveness of France; there is no limit in this regard. Growth will return; it is already beginning to return, and we must be ready to seize it.

Allow me to conclude by reminding you how strategic health and biomedical research are for the future of France. Innovation in the field of health is a sustainable source of well-being, income, and jobs creation. Life and health sciences will be one of the engines of our economy in the future, the knowledge economy.

The national loan could indeed finance certain investments in service of the health of our fellow citizens. I am thinking in particular, Madam Minister of Health, of the hospital-university institutes (IHU). These hospital-university institutes will be platforms for care, research, and teaching of world-class level organized around a coherent scientific project. They will need to recruit the best professionals, both French and foreign. They will need to attract private funds to accelerate their development. They will need to foster the creation alongside them, in close liaison with industrialists, of biotechnology SMEs.

I announce to you that in 2010, an international call for proposals will award the IHU label to five French centers. Because I would like us to target reference centers of a global dimension rather than spreading credits among everyone without having a ripple effect for your industry, for our economy, and for the health of your patients and our fellow citizens. I announce that the selection will be stringent because excellence is not decreed; it is earned. The IHUs will be a powerful factor of attractiveness for France. Their creation will mark - I hope - a tightening of relations between our country's research and the health industries.

Ladies and gentlemen,

I hope to have convinced you that France is changing, that it is changing quickly, and that the movement is not over, far from it. I look forward to seeing you at the beginning of 2012 on the occasion of a new meeting of the strategic council for health industries. Thanks to Mr. Thierry TUOT, who is in charge of overseeing the implementation of the measures announced today, we will then be able to see - I hope - that you will have invested and created jobs in France. There is no inevitability. I also hope that you have understood that, in the eyes of the public authorities, you, the health industry leaders, are a priority and that we consider it our duty to help you. There is a Minister of Industry, Christian ESTROSI, a Minister of Finance; we do not want to manage your affairs for you. We want to understand your problems in order to help you and so that you can develop research and industrial employment in France. That is what matters to us, and the State must be a support for the development of your industries and not a hindrance. That is what explains my presence alongside the ministers.

Thank you.